Advertisement

Topics

Can-Fite BioPharma Ltd Company Profile

11:59 EST 24th November 2017 | BioPortfolio

CAN-FITE BIOPHARMA LTD is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by Prof. Pnina Fishman, an investigator from Rabin Medical Center, and patent attorney Dr. Ilan Cohn, a senior partner at Reinhold Cohn Patent Attorneys. Prof. Pnina Fishman serves as the CEO of Can-Fite. The Company was founded on the basis of scientific findings made by Prof. Pnina Fishman and focuses on the development of small molecule-based drugs that bind to receptors of cancerous or inflammatory cells and inhibit their development. The leading drug of the company, CF101, is under advanced clinical development for inflammatory diseases and the second drug, CF102 is being developed for liver diseases, including liver cancer and viral Hepatitis C. Can-Fite has vast clinical experience. Thus far 700 patients participated in clinical trials done by the company.


News Articles [1461 Associated News Articles listed on BioPortfolio]

Can-Fite BioPharma???s Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Compelling unmet need for NAFLD/NASH drug to address estimated $35 billion treatment market by 2025 PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE...

Can-Fite’s former subsidiary OphthaliX merges with Wize Pharma

Can-Fite BioPharma says that its previously majority owned subsidiary OphthaliX has completed a merger with Wize Pharma.

Liver Cancer Drug Distribution Hitting Goals in Korea

NewsCan-Fite receives milestone payment from CKD Pharmaceuticals, its distribution partner in Korea. It marks the second payment in distribution agreement valued at up to $3M in upfront and milestone ...

Can-Fite commences Phase II trial of namodenoson for NAFLD/NASH

Israeli biotechnology firm Can-Fite BioPharma is set to commence patient enrolment for a Phase II clinical trial of namodenoson to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic ste...

Can-Fite BioPharma Receives Milestone Payment From Its Distribution Partner In Korea

  Life Sciences Jobs   ...

Can-Fite BioPharma Reports Second Quarter 2017 Financial Results & Provides Clinical Update

  Life Sciences Jobs   ...

Can-Fite BioPharma Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

  Life Sciences Jobs   ...

Can-Fite BioPharma CEO Dr. To Present As Expert Speaker At Europe In Frankfurt, Germany On October 12, 2017

  Life Sciences Jobs   ...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Comparing the sensitivity of auramine-rhodamine fluorescence to polymerase chain reaction in the detection of Mycobacterium leprae in Fite-negative tissue sections.

Applications of Raman Spectroscopy in Biopharmaceutical Manufacturing: A Short Review.

The production of active pharmaceutical ingredients (APIs) is currently undergoing its biggest transformation in a century. The changes are based on the rapid and dramatic introduction of protein- and...

On-line prediction of the glucose concentration of CHO cell cultivations by NIR and Raman spectroscopy: Comparative scalability test with a shake flask model system.

In this study, near-infrared (NIR) and Raman spectroscopy were compared in parallel to predict the glucose concentration of Chinese hamster ovary cell cultivations. A shake flask model system was used...

Multiplexing N-Glycan analysis by DNA analyzer.

Analysis of N-glycan structures has been gaining attentions over the years due to their critical importance to biopharma based applications and growing roles in biological research. Glycan profiling i...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [125 Associated Companies listed on BioPortfolio]

Can-Fite BioPharma Ltd

CAN-FITE BIOPHARMA LTD is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by Prof. Pnina Fishman, an in...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "Can-Fite BioPharma Ltd" on BioPortfolio

We have published hundreds of Can-Fite BioPharma Ltd news stories on BioPortfolio along with dozens of Can-Fite BioPharma Ltd Clinical Trials and PubMed Articles about Can-Fite BioPharma Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Can-Fite BioPharma Ltd Companies in our database. You can also find out about relevant Can-Fite BioPharma Ltd Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record